- Home
- MNOV vs NOMA Comparison
MNOV vs NOMA Comparison
Compare MNOV & NOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNOV | NOMA |
|---|---|---|
| Founded | 2000 | 2023 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Services-Misc. Amusement & Recreation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.9M | 59.1M |
| IPO Year | 2004 | 2025 |
Fundamental Metrics
Financial Performance| Metric | MNOV | NOMA |
|---|---|---|
| Price | $1.34 | $2.26 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $7.50 | N/A |
| AVG Volume (30 Days) | ★ 30.2K | 13.6K |
| Earning Date | 05-14-2026 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,360,807.00 | $6,376.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $180.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 194.15 | N/A |
| 52 Week Low | $1.17 | $2.00 |
| 52 Week High | $1.96 | $10.00 |
Technical Indicators
Market Signals| Indicator | MNOV | NOMA |
|---|---|---|
| Relative Strength Index (RSI) | 55.33 | 35.89 |
| Support Level | $1.27 | N/A |
| Resistance Level | $1.45 | $3.43 |
| Average True Range (ATR) | 0.04 | 0.39 |
| MACD | 0.01 | -0.07 |
| Stochastic Oscillator | 46.90 | 18.31 |
Price Performance
Historical ComparisonAbout MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.
About NOMA NOMADAR Corp.
Nomadar Corp operates at the intersection of sports and technology, focusing on high-performance training programs and cultural exchange. The company aims to connect athletes, coaches, and fans through inventive technological solutions, enhancing sports development beyond physical borders. It offers services like the High Performance Training (HPT) program and promotes the legacy of iconic athletes. The Company generates revenue through its High Performance Training Program and events management at the JP Financial Stadium.